| Title |
Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity
|
|---|---|
| Published in |
Current Atherosclerosis Reports, January 2016
|
| DOI | 10.1007/s11883-015-0555-0 |
| Pubmed ID | |
| Authors |
Michael D. Miedema, Joseph Huguelet, Salim S. Virani |
| Abstract |
Aspirin remains one of the most extensively studied cardiovascular medications in the history of medicine. However, despite multiple, well-designed, large randomized controlled trials evaluating the potential of aspirin to prevent cardiovascular events in individuals without known cardiovascular disease (CVD), the role of aspirin in primary prevention is currently unclear. The initial aspirin trials included largely low-risk individuals with primary outcomes mostly focused on myocardial infarction (MI) and stroke, and showed a significant reduction in these CVD outcomes, especially MI. The more recently conducted trials have focused on older, higher CVD risk populations with high rates of lipid-lowering and antihypertensive medications use. These studies have used broader CVD outcomes as their primary end points and have failed to show a significant benefit of aspirin therapy in primary prevention. The exact reasons for the lack of efficacy in these recent trials are unclear but may be related to low rate of atherothrombotic events relative to other CVD events in the populations studied. Four large randomized controlled trials are currently underway which should provide some clarity in determining the optimal use of aspirin in the primary prevention of CVD. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Argentina | 2 | 40% |
| Venezuela, Bolivarian Republic of | 1 | 20% |
| United States | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Science communicators (journalists, bloggers, editors) | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 5% |
| Netherlands | 1 | 5% |
| Germany | 1 | 5% |
| Unknown | 18 | 86% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 19% |
| Other | 2 | 10% |
| Student > Bachelor | 2 | 10% |
| Professor | 2 | 10% |
| Student > Ph. D. Student | 2 | 10% |
| Other | 4 | 19% |
| Unknown | 5 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 43% |
| Computer Science | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Unknown | 10 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2019.
All research outputs
#12,647,775
of 22,837,982 outputs
Outputs from Current Atherosclerosis Reports
#463
of 766 outputs
Outputs of similar age
#174,314
of 394,936 outputs
Outputs of similar age from Current Atherosclerosis Reports
#6
of 11 outputs
Altmetric has tracked 22,837,982 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 766 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 394,936 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.